                         SEQUENCE LISTING

<110>  Actinium Pharmaceuticals
       Berger, Mark
 
<120>  METHODS FOR TREATMENT OF PATIENTS WITH MYELODYPLASTIC SYNDROMES

<130>  PT17-046PCT

<150>  62/614,658
<151>  2018-01-08

<160>  1     

<170>  PatentIn version 3.5

<210>  1
<211>  364
<212>  PRT
<213>  Homo sapiens

<400>  1

Met Pro Leu Leu Leu Leu Leu Pro Leu Leu Trp Ala Gly Ala Leu Ala 
1               5                   10                  15      


Met Asp Pro Asn Phe Trp Leu Gln Val Gln Glu Ser Val Thr Val Gln 
            20                  25                  30          


Glu Gly Leu Cys Val Leu Val Pro Cys Thr Phe Phe His Pro Ile Pro 
        35                  40                  45              


Tyr Tyr Asp Lys Asn Ser Pro Val His Gly Tyr Trp Phe Arg Glu Gly 
    50                  55                  60                  


Ala Ile Ile Ser Arg Asp Ser Pro Val Ala Thr Asn Lys Leu Asp Gln 
65                  70                  75                  80  


Glu Val Gln Glu Glu Thr Gln Gly Arg Phe Arg Leu Leu Gly Asp Pro 
                85                  90                  95      


Ser Arg Asn Asn Cys Ser Leu Ser Ile Val Asp Ala Arg Arg Arg Asp 
            100                 105                 110         


Asn Gly Ser Tyr Phe Phe Arg Met Glu Arg Gly Ser Thr Lys Tyr Ser 
        115                 120                 125             


Tyr Lys Ser Pro Gln Leu Ser Val His Val Thr Asp Leu Thr His Arg 
    130                 135                 140                 


Pro Lys Ile Leu Ile Pro Gly Thr Leu Glu Pro Gly His Ser Lys Asn 
145                 150                 155                 160 


Leu Thr Cys Ser Val Ser Trp Ala Cys Glu Gln Gly Thr Pro Pro Ile 
                165                 170                 175     


Phe Ser Trp Leu Ser Ala Ala Pro Thr Ser Leu Gly Pro Arg Thr Thr 
            180                 185                 190         


His Ser Ser Val Leu Ile Ile Thr Pro Arg Pro Gln Asp His Gly Thr 
        195                 200                 205             


Asn Leu Thr Cys Gln Val Lys Phe Ala Gly Ala Gly Val Thr Thr Glu 
    210                 215                 220                 


Arg Thr Ile Gln Leu Asn Val Thr Tyr Val Pro Gln Asn Pro Thr Thr 
225                 230                 235                 240 


Gly Ile Phe Pro Gly Asp Gly Ser Gly Lys Gln Glu Thr Arg Ala Gly 
                245                 250                 255     


Val Val His Gly Ala Ile Gly Gly Ala Gly Val Thr Ala Leu Leu Ala 
            260                 265                 270         


Leu Cys Leu Cys Leu Ile Phe Phe Ile Val Lys Thr His Arg Arg Lys 
        275                 280                 285             


Ala Ala Arg Thr Ala Val Gly Arg Asn Asp Thr His Pro Thr Thr Gly 
    290                 295                 300                 


Ser Ala Ser Pro Lys His Gln Lys Lys Ser Lys Leu His Gly Pro Thr 
305                 310                 315                 320 


Glu Thr Ser Ser Cys Ser Gly Ala Ala Pro Thr Val Glu Met Asp Glu 
                325                 330                 335     


Glu Leu His Tyr Ala Ser Leu Asn Phe His Gly Met Asn Pro Ser Lys 
            340                 345                 350         


Asp Thr Ser Thr Glu Tyr Ser Glu Val Arg Thr Gln 
        355                 360                 


